PARIS, France, September 29, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic treatments that exploit the body’s natural regulatory mechanisms in order to modulate the immune response in patients suffering from chronic inflammatory diseases, today announces the publication of its 2023 half-year financial report.
The 2023 half-year financial report is available on the Company’s website (www.abivax.com – “Investors”).
About Abivax
Abivax is a clinical-stage biotechnology company focused on developing therapeutic treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients suffering from chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical development for the treatment of moderately to severely active ulcerative colitis. For more information about the Company, visit www.abivax.com/fr. Also follow us on X (formerly Twitter) @ABIVAX_.